TUBB
Tubulin beta chain
As of the edition of 20 October 2026, TUBB (tubulin beta chain, UniProt P07437) has 46 drugs tested at it and 16 companies on the list, 5 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P07437
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 21
- Disease areas
- Cancer; Skin and connective tissue; Urinary and reproductive; Lungs and airways; Digestive system; Blood and lymph; Immune system; Pregnancy and women's health
- Registered trials of its drugs
- 7,727
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 17 |
| Active | 5 |
| Went quiet | 16 |
| Stopped | 7 |
| Status not established | 1 |
| Total | 46 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Paclitaxel | Marketed | Phase 4 | none listed |
| Docetaxel anhydrous | Marketed | Phase 4 | none listed |
| Vincristine | Marketed | Phase 4 | none listed |
| Vinorelbine | Marketed | Phase 4 | none listed |
| Colchicine | Marketed | Phase 4 | none listed |
| Brentuximab vedotin | Marketed | Phase 4 | Ends 2029 |
| Eribulin | Marketed | Phase 4 | Ended 2026 |
| Vinblastine | Marketed | Phase 4 | none listed |
| Trastuzumab emtansine | Marketed | Phase 4 | Ended 2025 |
| Cabazitaxel | Marketed | Phase 4 | Ended 2025 |
| Ixabepilone | Marketed | Phase 3 | none listed |
| Polatuzumab vedotin | Marketed | Phase 3 | Ends 2031 |
12 of 46 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 5 |
| Engaged | 6 |
| Total on the list | 16 |
The other 13 companies at TUBB
In the product16 companies in all; 13 are not named here, and no score is.
See the 16 companies at TUBB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.